Skip to content
Search

Latest Stories

ICBs to oversee commissioning of all vaccination services from April 2026

Commissioning pharmacies to deliver a wide range of NHS vaccinations would free up 10 million GP vaccination appointments each year
Commissioning pharmacies to deliver a wide range of NHS vaccinations would free up 10 million GP vaccination appointments each year (gettyimages)

Commissioning pharmacies to deliver more NHS vaccinations could free up 10 million GP appointments annually, says CCA.

From 1 April 2026, integrated care boards (ICBs) will become responsible for commissioning all vaccination services, as part of NHS England’s plan to delegate vaccination and screening (V&S) programmes.

The proposal has been considered by the Vaccination and Screening Delivery and Transformation Board, Commissioning Development Programme Delivery Group, and the NHS Executive, with the delegation now requesting approval from the NHS England Board.


Commenting on the proposal, Malcolm Harrison, chief executive, Company Chemists’ Association (CCA) has emphasised the crucial role community pharmacies can play in improving vaccine uptake, particularly in underserved communities.

Harrison said that the most efficient approach for many NHS vaccinations was to “provide a consistent patient offer through nationally defined programmes” as this “ensures that patients nationwide know what to expect of their local pharmacy and supports uptake rates.”

However, he recognised that ICB-led commissioning can also “provide opportunities to commission bespoke vaccination and screening services, based on local and unmet need.”

“Community pharmacy has a clear role to play in meeting patient need and increasing uptake for both national and local programmes,” he noted.

Harrison also highlighted that the CCA’s Pharmacy Vaccinations Development Group, launched last year, is already working with representatives across the supply chain to explore how pharmacies can administer more NHS vaccines.

The association is calling on NHS England to commission pharmacies to deliver a wide range of NHS vaccinations – including pneumonia, shingles, meningitis, RSV, and other routine childhood vaccinations.  

“Taken together, this would free up 10 million GP vaccination appointments each year, allowing GPs to focus on delivering care to patients with more complex care needs,” Harrison added.

The NHS aims to delegate the majority of V&S services to ICBs to support their role in population health and prevention.

In addition to commissioning all vaccination services, most components of screening services have been delegated to ICBs.

However, five components of screening services will remain under NHS England’s direct commissioning:

  • Bowel cancer screening hubs
  • Bowel cancer screening managed service provision
  • Cervical Screening Administration Service (CSAS)
  • HPV cytology laboratories
  • Newborn bloodspot laboratory services

NHS England also retain its role in standard setting, assurance, coordination, planning, implementing new programmes, managing programme changes, and incident response to ensure national consistency.

 

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less